Clinical Trial Update: Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the effect on liver fat and metabolic parameters when switching a protease inhibitor or efavirenz to raltegravir in HIV patients with m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Metabolic Syndrome
• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• EFAVIRENZ (efavirenz)
• Protease inhibitor (protease inhibitor)
• Raltegravir (raltegravir)

Snippet

Sponsor: Helsinki University Central Hospital | Conditions: HIV Seropositivity, Metabolic Syndrome | Phase 4 | Status: COMPLETED | Results posted: 2021-07-07